Proactive Investors - Run By Investors For Investors

CytoDyn to present data on monoclonal antibody treatment of HIV at Seattle conference

The company is completing a biologics license application with the FDA for leronlimab's use in combination therapy
A syringe
The company's once-weekly leronlimab injection is designed to block HIV-1

CytoDyn Inc (OTCMKTS:CYDY) said Wednesday that data from the study of its monoclonal antibody treatment of HIV will be presented at a Seattle conference.

The biotech company said in a statement that the data will be presented at the Conference on Retroviruses and Opportunistic Infections on March 7.

The company’s leronlimab candidate is a once-weekly injection designed to block HIV-1 from entering and infecting human cells by binding to the CCR5 receptor, a protein on the surface of white blood cells that is related to the immune system.

DEEP DIVE: CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial

CytoDyn’s commitment to providing groundbreaking therapeutic advances for those in need has never been stronger,” CEO Nader Pourhassan said. “We remain highly encouraged by the continued clinical and regulatory progress to bring the next generation HIV treatment to patients.”

The company is in the process of completing a biologics license application with the Food and Drug Administration for leronlimab, also known as PRO 140, as part of a combination with highly active antiretroviral therapies for HIV-infected patients.

Then, subject to the treatment's approval by the FDA as part of a combination therapy, CytoDyn plans to file for a label expansion for leronlimab as a monotherapy, providing the company can achieve positive results from a proposed Phase 3 trial.

The annual conference brings together clinical researchers from around the world to share the latest studies in the battle against HIV, AIDS and related infectious diseases. It will be held from March 4 to March 7 at the Washington State Convention Center in Seattle.

Contact Dennis Fitzgerald at [email protected]

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
child
February 08 2019
“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond”
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use